Detalles de la búsqueda
1.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Diabetes Obes Metab
; 25(6): 1485-1494, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36708333
2.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
Diabetes Obes Metab
; 24(4): 713-721, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981621
3.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Diabetes Obes Metab
; 24(9): 1819-1828, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589611
4.
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.
Eur J Drug Metab Pharmacokinet
; 48(6): 675-689, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792130
Resultados
1 -
4
de 4
1
Próxima >
>>